ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma

Zhang, Zhengfeng; Yang, Lei; Wang, Dazhen; Ruan, Yuli; Zhang, Jianji; Zhao, Lu; Yang, Liu; Lou, Changjie*哈尔滨医科大学
Therapeutic Advances in Medical Oncology2023DOI: 10.1177/17588359231169981
2被引4阅读
引用收藏
分享

摘要

Objective:To investigate the efficacy and safety differences between the cisplatin + paclitaxel (TP) and cisplatin + fluorouracil (PF) regimens in combination with or without immune checkpoint inhibitors (ICIs) in advanced esophageal squamous cell carcinoma (ESCC) first-line treatment and prognostic factors. Methods:We selected the medical records of patients with late stage ESCC admitted to the hospital between 2019 and 2021. Based on the first-line treatment regimen, control groups were divided into chemotherapy plus ICIs (n = 243) and non-ICIs (n = 171), 119 (49%) in the TP + ICIs group, 124 (51%) in the PF + ICIs group, 83 (48.5%) in the TP group, and 88 (51.5%) in the PF group in the control group. We analyzed and compared factors related to efficacy, safety, or response to toxicity and prognosis across four subgroups. Results:The overall objective response rate (ORR) and disease control rate (DCR) of the TP plus ICIs group were 42.1% (50/119) and 97.5% (116/119), respectively, which were 6.6% and 7.2% higher than those of the PF plus ICIs group. Patients in the TP combined with ICIs group had higher overall survival (OS) and progression-free survival (PFS) than those in the PF combined with ICIs group [hazard ratio (HR) = 1.702, 95% confidence interval (CI): 0.767-1.499, p = 0.0167 and HR = 1.158, 95% CI: 0.828-1.619, p = 0.0055] ORR and DCR were 15.7% (13/83) and 85.5% (71/83) in the TP chemotherapy alone group, significantly higher than the PF group [13.6% (12/88) and 72.2% (64/88)] (p < 0.05), OS and PFS were also better in patients treated with TP regimen chemotherapy than PF (HR = 1.173, 95% CI: 0.748-1.839, p = 0.0014 and HR = 0.1.245, 95% CI: 0.711-2.183, p = 0.0061). Furthermore, following the combination of TP and PF diets with ICIs, the OS of the patients was higher than that of the group treated with chemotherapy alone (HR = 0.526, 95% CI: 0.348-0.796, p = 0.0023 and HR = 0.781, 95% CI: 0.0.491-1.244, p < 0.001). Regression analysis showed that the neutrophil-to-lymphocyte ratio (NLR), the control nuclear status score (CONUT), and the systematic immune inflammation index (SII) were independent prognostic factors for the efficacy of immunotherapy (p < 0.05). The overall incidence of treatment-associated adverse events (TRAEs) was 79.4% (193/243) and 60.8% (104/171) in the experimental and control groups, respectively, and there was no statistically significant difference in TRAEs between TP + ICIs (80.6%) and PF + ICIs (78.2%) (61.4%) and PF groups (60.2%) (p > 0.05). Overall, 21.0% (51/243) of patients in the experimental group experienced immune-related adverse events (irAEs), and all of these adverse effects were tolerated or remitted following drug treatment without affecting follow-up. Conclusion:The TP regimen was associated with better PFS and OS with or without ICIs. Furthermore, high CONUT scores, high NLR ratios, and high SII were found to be associated with poor prognosis in combination immunotherapy.

学科与关键词

关键词
advanced esophageal squamous carcinomachemotherapyimmunotherapyPFTP
相关
加载中…
  • Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
    Ma, Yue; Xin, Yu; Su, Dan; Zhou, Yuxin; Li, Hongxu; Zou, Haoyi; Yu, Xuefan; Yang, Qing; Cui, Jie; Wang, Changsong*; Zhang, Yanqiao*Frontiers in Oncology, 2022, 12: 958783.
  • Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis
    Zhang, Yangfeng; Li, Chunhui; Du, Kunpeng; Pengkhun, Nov; Huang, Zijian; Gong, Min; Li, Yanyang; Liu, Xiang; Li, Lilin; Wang, Duanyu; Wang, Changqian; Chen, Fengsheng*; Li, Jiqiang*Immunotherapy, 2023, 15(10): 737-750.被引 1
  • Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis
    Gao, Zhen; Huang, Shujie; Wang, Sichao; Tang, Dezhao; Xu, Wei; Zeng, Ruijie; Qiao, Guibin*LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 38: 100841.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Medical Oncology
发表日期
2023
卷期
第 15 卷
页码
17588359231169981
DOI
10.1177/17588359231169981
语言
ENGLISH
成果收录
SCIE

作者

  • Z

    Zhang, Zhengfeng (第一作者)

    harbin med univ

  • Y

    Yang, Lei

    harbin med univ

查看全部 8 位作者收起作者
  • W

    Wang, Dazhen

    harbin med univ

  • R

    Ruan, Yuli

    harbin med univ

  • Z

    Zhang, Jianji

  • Z

    Zhao, Lu

    harbin med univ

  • Y

    Yang, Liu

    harbin med univ

  • L

    Lou, Changjie (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417